1. Introduction {#sec1}
===============

Lots of studies found increased serum uric acid (sUA) levels in subjects with metabolic syndrome (MetS) or cardiovascular disease, and sUA is associated with several components of MetS, including dyslipidemia, hypertension, impaired glucose metabolism, and obesity \[[@B1]--[@B3]\]. Some recent studies have already highlighted the connection between sUA and glucose homeostasis. For example, the Rotterdam Study showed that the subjects with higher levels of sUA were at higher risk of type 2 diabetes \[[@B4]\], and a modest positive association between plasma uric acid concentration and the incidence of type 2 diabetes in Chinese individuals was suggested by Chien et al. \[[@B5]\]. As is known, both insulin resistance and *β*-cell dysfunction play determinate roles in the pathogenesis of type 2 diabetes \[[@B6]\]. The correlation between sUA and insulin resistance has been verified by several researches years ago \[[@B7], [@B8]\], and insulin resistance is thought to be the principal underlying pathophysiologic abnormality connecting hyperuricemia and components of MetS. However, most previous studies were performed on nondiabetic subjects. Furthermore, few studies focused on the relationship between sUA level and islet *β*-cell dysfunction, and whether there is a corresponding change of sUA level with *β*-cell function deterioration in type 2 diabetes is unknown. In this cross-sectional study, we investigated the association between sUA and *β*-cell function as well as insulin sensitivity in patients with type 2 diabetes, and we further elucidate the time-dependent changes of insulin secretion ability in different gender and uric acid level groups.

2. Materials and Methods {#sec2}
========================

2.1. Study Subjects {#sec2.1}
-------------------

One thousand and twenty-one patients with type 2 diabetes who received treatment in the First Affiliated Hospital of Nanjing Medical University between 2008 and 2011 were enrolled in this study. Type 2 diabetes mellitus was diagnosed according to the criteria of the American Diabetes Association \[[@B9]\]. The maximum duration of diabetes was 35 years. The average age of all patients was 56.86 ± 12.34 (mean ± SD) years old. Meanwhile, body mass index (BMI) and sUA were 25.10 ± 3.50 kg/m^2^ and 299.08 ± 88.96 *μ*mol/L, respectively. Patients with severe pancreatic disease, liver disease, and renal disease and those who suffered recent diabetic ketoacidosis and hyperosmotic nonketotic diabetic coma were excluded. Verbal informed consent was obtained from all participants. The study was approved by the ethics committee of the First Affiliated Hospital of Nanjing Medical University.

2.2. Measurements {#sec2.2}
-----------------

In all subjects, the height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured and recorded. History of hypertension, family history of diabetes (FHD), and the years from diagnosis of type 2 diabetes were inquired. If one of parents, siblings, or grandparents had been diagnosed with diabetes, patient was defined as having FHD. All patients stopped using antidiabetic medicine at least one day before the blood samples are taken. After 10--12 hours overnight fasting, venous blood samples were collected to measure uric acid, glycated haemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), alanine aminotransferase (ALT), fasting plasma glucose (G0), and fasting serum insulin (I0). Then the 75 g oral glucose tolerance test (OGTT) and insulin secretion test were performed, and venous blood samples were obtained at 30 and 120 minutes after glucose load for measuring the plasma glucose (G30, G120) and serum insulin (I30, I120).

Plasma glucose concentrations were measured using the hexokinase method (OLYMPUS AU5400). HbA1c and serum insulin were measured by high performance liquid chromatography (Bio-Rad D10) and radioimmunoassay (Iodine \[^125^I\] Insulin Radioimmunoassay Kit, Beijing North Institute of Biological Technology), respectively. ALT and serum lipid profiles, including TG, HDL, and LDL, were determined with an automatic biochemical analyzer (HITACHI 7020).

2.3. Calculations {#sec2.3}
-----------------

BMI was calculated through dividing weight (kg) by square of height (m). To evaluate the insulin secretion, InsAUC30/GluAUC30 (INSR30) was calculated as a surrogate index for the early phase insulin secretion and InsAUC120/GluAUC120 (INSR120) as a surrogate index for total insulin secretion, where InsAUC30 and GluAUC30 are the area under insulin (mIU/L) and glucose (mmol/L) curves during 0 to 30 min of the OGTT and InsAUC120 and GluAUC120 are the area under insulin and glucose curves during 0 to 120 min, respectively \[[@B10]\]. Matsuda insulin sensitivity index (Matsuda ISI, calculated as $10000/\sqrt{(\text{G}0 \times \text{I}0) \times (\overset{-}{\text{G}} \times \overset{-}{\text{I}})}$, where $\overset{-}{\text{G}}$ and $\overset{-}{\text{I}}$ are the average levels of plasma glucose (mg/dL) and insulin (mIU/L) during OGTT) was chosen to evaluate insulin sensitivity \[[@B11]\]. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as follows: insulin (mIU/L) × glucose (mmol/L)/22.5 \[[@B12]\]. Glucose disposition indices (disposition index 30 = DI30 = Matsuda ISI × INSR30, disposition index 120 = DI120 = Matsuda ISI × INSR120) \[[@B10], [@B13]\] were used to assess *β*-cell function, combining both insulin secretion and insulin sensitivity.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Student\'s*t*-test and the chi-square test were used to analyze group differences. The correlativity between sUA and *β*-cell function was analyzed by Pearson\'s correlation. The multiple linear regression analysis was applied to test the associations between *β*-cell function and sUA after adjustment for several covariates. Abnormally distributed continuous variables, including HbA1c, TG, and ALT, as well as all the indices for insulin sensitivity and *β*-cell function, were log-transformed to yield an approximately normal distribution before statistical analysis. *P* value \< 0.05 (two-tailed) was considered statistically significant. All statistical analyses were conducted with the Statistical Package for Social Science for Windows (SPSS, version 13.0).

3. Results {#sec3}
==========

The characteristic of the study patients was shown in [Table 1](#tab1){ref-type="table"}. The patients were divided into two groups according to the median sUA levels of females and males, respectively (LUA: low serum uric acid, which was under the median sUA level; HUA: high serum uric acid, which was above the median sUA level). Patients with HUA had higher levels of BMI, TG, and ALT and greater ratio of hypertension in both genders. In contrast, the HbA1c and HDL were lower in HUA groups than in LUA ones. In male, female, and total groups, HUA patients had greater HOMA-IR and smaller Matsuda ISI than LUA subjects. Consistent with insulin resistance, patients with HUA had greater insulin secretion indices, that is, INSR30 and INSR120, than LUA in all groups. Interestingly, we found that in men and total groups, patients with HUA had greater disposition indices (both DI30 and DI120) rather than in women group. Statistically significant correlations were found between sUA level and all the indices of *β*-cell function and insulin sensitivity either totally or after being stratified by gender (shown in [Table 2](#tab2){ref-type="table"}).

To exclude confounding factors which may influence *β*-cell function, multiple linear regression was carried out using all clinical parameters which were significantly correlated with *β*-cell function indices (data of correlation was not shown) as independent variables and indices of *β*-cell function as dependent variables. The results of multiple linear regression analysis are shown in [Table 3](#tab3){ref-type="table"}. The sUA was independently associated with INSR30 and INSR120 (*P* value of both partial regression coefficients was less than 0.001) after adjustment for sex, hypertension, years from diagnosis, BMI, HbA1c, TG, HDL, ALT, and HOMA-IR. In the regression model of DI30 and DI120, the relationship between sUA and disposition indices was statistically significant (*P* value of both partial regression coefficients was less than 0.001) after adjustment for years from diagnosis, SBP, DBP, HbA1c, TC, LDL, and HOMA-IR. After grouping patients by sex, the regression models of *β*-cell function were shown in [Table 4](#tab4){ref-type="table"}. Serum uric acid remained significantly associated with insulin secretion indices (INSR30 and INSR120) and disposition indices (DI30 and DI120) after adjusting for potential confounding factors in both female and male groups (all *P* value of partial regression coefficients was less than 0.05).

We also investigated the differences of *β*-cell function changes along with disease duration between low and high sUA levels. In the scattered plots displayed in Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, in both females and males, INSR30 and INSR120 decreased along with disease duration in both HUA and LUA group (all regression coefficients were negative, *P* \< 0.05). Interestingly, although INSR30 and INSR120 were higher in HUA group at the early stage of diabetes, they superficially decreased more rapidly along with disease duration than in LUA group and finally dropped to almost the same level as the LUA group. However, the difference of slop of the lines was not statistically significant after adjusting for confounding factors including hypertension, BMI, HbA1c, TG, HDL, ALT, and HOMA-IR. For disposition indices, in HUA group, DI30 and DI120 significantly dropped as disease duration increased in both females and males. However, in LUA group, no significant regression was found between disposition indices and disease duration in both genders, except for DI120 in females.

4. Discussion {#sec4}
=============

The failure of pancreatic *β*-cell function plays an important role in the pathogenesis of type 2 diabetes. Previous studies have shown that impaired insulin secretion is the key in the conversion from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) and diabetes \[[@B14], [@B15]\], and the deterioration of *β*-cell function does not stop after diagnosis. The United Kingdom Prospective Diabetes Study (UKPDS) showed that *β*-cell function, assessed by homeostasis model assessment (HOMA), decreased approximately by 25% in the first 5 years of diabetes \[[@B16]\]. Several factors, including hyperglycemia, dyslipidemia, cytokines secreted by adipocytes, and immune response, have been proposed as reasons for pancreatic *β*-cell function deterioration \[[@B17]--[@B19]\]. In addition, our study found the close relationship between sUA and insulin secretion ability as well as glucose disposition indices, which was rarely concerned in previous studies.

Concerning the relationship between sUA level and two critical sides in the pathogenesis of type 2 diabetes, that is, insulin resistance and *β*-cell dysfunction, the interrelationship between sUA and insulin resistance was revealed by several studies years ago \[[@B7], [@B8]\]. Our present study verified this relationship again by calculating the insulin sensitivity by either Matsuda ISI or HOMA-IR. Elevated sUA level usually accompanies insulin resistance. Higher insulin levels can reduce renal excretion of urate and enhance renal urate reabsorption with increased renal tubular reabsorption of sodium \[[@B7], [@B20], [@B21]\]. In addition, increased purine biosynthesis and turnover, with its attendant increase in sUA, link high sUA to insulin resistance and/or hyperinsulinaemia by increased activity of the hexose monophosphate shunt \[[@B22]\]. On the other hand, sUA not only may be a consequence of insulin resistance but also may actually promote or worsen insulin resistance. Specifically, a recent study showed that sUA plays an important role in the pathogenesis of MetS, possibly due to its ability to inhibit endothelial function. In detail, sUA has been shown to inhibit nitric oxide (NO) bioavailability and reduce NO concentration which is required in insulin stimulated glucose uptake \[[@B23], [@B24]\]. Consequently, higher sUA always keeps with more severe insulin resistance, that is, greater insulin demand of our organs.

Few previous researches investigated the interaction between *β*-cell function and sUA. In present study, we reported the correlation between sUA level and indices reflecting islet insulin secretion ability. Subjects with higher levels of sUA had higher insulin secretion, including the early phase (INSR30) and total (INSR120) insulin secretion, and after adjustment for variables associated with insulin resistance including BMI, TG, ALT, and HOMA-IR, sUA is still independently associated with insulin secretion. The reason why patients with type 2 diabetes of HUA group can secrete more insulin at the early stage was temporarily unknown. Insulin resistance may be one of the suppositional reasons, and the increased insulin secretion may be considered as a compensatory response to overcome the insulin resistance. Although subjects with higher sUA secrete more insulin, it does not mean that high sUA is beneficial to *β*-cell function. The insulin secretion ability in those seems to drop more rapidly than those having lower sUA as type 2 diabetes duration extends. At last, when the disease duration is long enough, the difference of both INSR30 and INSR120 between HUA and LUA groups diminishes. A recent study provided evidence that sUA has a direct negative effect on *β*-cell function, which could cause *β*-cell death and dysfunction by activation of the NF-*κ*B and iNOS-NO signal axis. This may partly explain the reason why insulin secretion ability seems to drop more rapidly in HUA group \[[@B25]\]. Nevertheless, the profound physiology changes connecting uric acid metabolism and insulin secretion is still worth further investigation.

Disposition indices which reflect the real glucose metabolism give attention to both insulin sensitivity and insulin secretion after glucose load. In our research, the sUA always kept positive association with disposition indices in total patients and after having been divided into gender groups. This finding is consistent with the result also got in our study that those subjects with higher sUA got statistically lower HbA1c level. All these suggest that high sUA level is associated with better glucose utilization. A mechanism underlying the relationship between glucose utilization and sUA levels may be due to the uricosuric effect of glycosuria, which means hyperglycemia facilitates uric acid excretion when the blood glucose level is above 10 mmol/L \[[@B26]\]. By glycosuria, the sUA concentration of patients with high blood glucose levels may be low; however high blood glucose is harmful to islet *β*-cells. Furthermore, some studies demonstrated high sUA levels are associated with increased generation of free radicals and oxidative stress \[[@B27]\], which has various adverse effects on *β*-cell function \[[@B28], [@B29]\]. This could be one possible reason for the faster decline of insulin secretion function in high sUA patients. However, other studies have suggested that sUA is an effective antioxidant \[[@B30], [@B31]\] and elevated sUA levels may reflect a compensatory mechanism contributing to the increased oxidative stress associated with the MetS. Collectively, the exact role of sUA in oxidation is still controversial, and further research is required.

We are very cautious about making conclusion in the close relation between sUA and *β*-cell insulin secretion function as well as glucose disposition because of two points: firstly, this is just a cross-sectional study rather than longitudinal study; secondly, subjects in our study received a wide diversity of hypoglycemic therapy which might influence the nature change of the islet function.

However, from this study, an independent positive association between sUA and *β*-cell function is confirmed, suggesting a potential close relation and interaction between uric acid and insulin secretion ability. Type 2 diabetic patients with higher sUA level have better insulin secretion but their residual *β*-cell function seems to decay more quickly.
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![Scattered plots of simple linear regression between *β*-cell function and years from diagnosis in females. LUA, sUA levels under median of females; HUA, sUA levels above median of females. All *β*-cell function indices (INSR30, INSR30, DI30, and DI120) were log-transformed. Only significant regression lines and formulas are shown. All regression coefficients were negative. The decreases of INSR30, INSR120, and DI120 per year in the HUA group were greater than that in LUA group.](JDR2014-709691.001){#fig1}

![Scattered plots of simple linear regression between *β*-cell function and years from diagnosis in males. LUA, sUA levels under median of men; HUA, sUA levels above median of males. All *β*-cell function indices (INSR30, INSR30, DI30, and DI120) were log-transformed. Only significant regression lines and formulas are shown. All regression coefficients were negative. The decreases of INSR30 and INSR120 per year in the HUA group were greater than that in LUA group.](JDR2014-709691.002){#fig2}

###### 

Baseline characteristics of subjects grouped by gender and serum uric acid levels (mean ± SD or number).

                          Female           Male                 Total                                                  
  ----------------------- ---------------- -------------------- ---------------- -------------------- ---------------- --------------------
  sUA (*μ*mol/L)          207.61 ± 38.31   339.84 ± 71.25^\#^   250.19 ± 46.47   383.06 ± 61.04^\#^   232.74 ± 48.08   365.29 ± 68.73^\#^
  Age (yr)                57.83 ± 11.11    61.40 ± 11.42^†^     55.65 ± 11.63    54.23 ± 13.52        56.54 ± 11.45    57.18 ± 13.16
  Years from diagnosis    6.19 ± 6.36      6.24 ± 5.72          5.82 ± 6.22      5.16 ± 5.72          5.97 ± 6.27      5.60 ± 5.74
  Hypertension (yes/no)   85/124           146/64^\#^           115/186          149/152^†^           200/310          295/216^\#^
  FDM (yes/no)            78/131           80/130               123/178          113/188              201/309          213/308
  SBP (mmHg)              133.04 ± 16.71   135.33 ± 16.52       131.33 ± 14.95   133.00 ± 16.15       132.03 ± 15.70   133.96 ± 16.33
  DBP (mmHg)              81.46 ± 9.35     81.85 ± 10.29        82.56 ± 9.83     83.94 ± 9.74         82.11 ± 9.65     83.08 ± 10.01
  BMI (kg/m^2^)           24.39 ± 3.67     25.87 ± 3.62^\#^     24.24 ± 3.26     25.92 ± 3.22^\#^     24.29 ± 3.43     25.90 ± 3.38^\#^
  HbA1c (%)               9.51 ± 2.51      8.85 ± 2.39^†^       9.83 ± 2.55      9.15 ± 2.39^†^       9.70 ± 2.53      9.02 ± 2.39^\#^
  TC (mmol/L)             4.99 ± 1.18      5.09 ± 1.15          4.70 ± 1.13      4.74 ± 1.10          4.81 ± 1.15      4.88 ± 1.13
  TG (mmol/L)             1.57 ± 1.17      1.90 ± 1.30^\#^      1.57 ± 1.39      2.27 ± 2.21^\#^      1.56 ± 1.30      2.11 ± 1.89^\#^
  HDL (mmol/L)            1.25 ± 0.32      1.17 ± 0.28^†^       1.15 ± 0.32      1.01 ± 0.23^\#^      1.19 ± 0.32      1.07 ± 0.26^\#^
  LDL (mmol/L)            3.12 ± 0.87      3.19 ± 0.84          3.00 ± 0.79      3.03 ± 0.74          3.05 ± 0.82      3.09 ± 0.78
  ALT (IU/L)              25.17 ± 18.35    28.52 ± 25.71        25.65 ± 18.95    33.65 ± 25.17^\#^    25.45 ± 18.69    31.54 ± 25.49^\#^
  INSR30                  1.31 ± 1.01      1.78 ± 1.13^\#^      0.99 ± 0.76      1.56 ± 1.12^\#^      1.12 ± 0.88      1.65 ± 1.12^\#^
  INSR120                 1.59 ± 1.43      2.29 ± 1.76^\#^      1.18 ± 1.08      1.94 ± 1.59^\#^      1.34 ± 1.25      2.08 ± 1.66^\#^
  DI30                    7.10 ± 3.89      7.35 ± 3.59          6.49 ± 3.20      7.47 ± 3.65^\#^      6.74 ± 3.50      7.41 ± 3.62^\#^
  DI120                   8.52 ± 5.78      9.10 ± 4.94          7.61 ± 4.35      9.23 ± 5.46^\#^      7.97 ± 5.00      9.17 ± 5.24^\#^
  HOMA-IR                 2.46 ± 1.73      3.04 ± 1.86^\#^      2.02 ± 1.48      2.71 ± 1.89^\#^      2.20 ± 1.59      2.84 ± 1.88^\#^
  Matsuda ISI             7.27 ± 4.71      5.17 ± 3.11^\#^      8.99 ± 5.48      6.36 ± 3.93^\#^      8.28 ± 5.24      5.87 ± 3.65^\#^

Abnormally distributed continuous variables, including HbA1c, TG, ALT, INS0, INS30, INS120, INSR30, INSR120, DI30, DI120, HOMA-IR, and Matsuda ISI, were log-transformed for analysis; nontransformed values were displayed for ease of interpretation. Differences between the LUA and HUA group were estimated using unpaired Student\'s *t*-test (or chi-square test for classified data). ^†^ *P* \< 0.01; ^\#^ *P* \< 0.001.

###### 

Correlations between serum uric acid level and *β*-cell function as well as insulin sensitivity.

                Total        Female       Male
  ------------- ------------ ------------ ------------
  INSR30        0.301^\#^    0.290^\#^    0.395^\#^
  INSR120       0.296^\#^    0.275^\#^    0.393^\#^
  DI30          0.150^\#^    0.100\*      0.206^\#^
  DI120         0.166^\#^    0.115\*      0.226^\#^
  HOMA-IR       0.192^\#^    0.216^\#^    0.241^\#^
  Matsuda ISI   −0.252^\#^   −0.261^\#^   −0.336^\#^

All abnormally distributed continuous variables were log-transformed. \**P* \< 0.05; ^\#^ *P* \< 0.001.

###### 

Multiple linear regression for *β*-cell function in total patients.

                                   INSR30   INSR120      DI30     DI120                                       
  -------------------------------- -------- ------------ -------- ------------ -------- ------------ -------- ------------
  Sex (0 = female, 1 = male)       −0.201   −0.136^\#^   −0.229   −0.139^\#^   ---      ---          ---      ---
  Hypertension (yes = 1, no = 0)   −0.026   −0.018       −0.018   −0.011       ---      ---          ---      ---
  Years from diagnosis             −0.020   −0.165^\#^   −0.029   −0.218^\#^   −0.016   −0.217^\#^   −0.026   −0.287^\#^
  BMI (kg^2^/cm)                   0.021    0.005^\#^    0.018    0.076^†^     ---      ---          ---      ---
  SBP (mmHg)                       ---      ---          ---      ---          0.002    0.055        0.001    0.021
  DBP (mmHg)                       ---      ---          ---      ---          −0.005   −0.099^†^    −0.006   −0.111^\#^
  HbA1c (%)                        −0.116   −0.400^\#^   −0.156   −0.479^\#^   −0.075   −0.414^\#^   −0.114   −0.527^\#^
  sUA (*μ*mol/L)                   0.001    0.147^\#^    0.001    0.146^\#^    0.001    0.154^\#^    0.001    0.156^\#^
  TG (mmol/L)                      −0.006   −0.005       0.015    0.012        ---      ---          ---      ---
  TC (mmol/L)                      ---      ---          ---      ---          −0.011   −0.029       −0.019   −0.040
  HDL (mmol/L)                     −0.077   −0.032       −0.098   −0.036       ---      ---          ---      ---
  LDL (mmol/L)                     ---      ---          ---      ---          −0.007   −0.012       0.009    0.014
  ALT (IU/L)                       0.091    0.076^†^     0.103    0.077^†^     ---      ---          ---      ---
  HOMA-IR                          0.497    0.455^\#^    0.426    0.349^\#^    −0.222   −0.326^\#^   −0.279   −0.343^\#^

*Β*: partial regression coefficient; S-*β*: standard partial regression coefficient. All abnormally distributed continuous variables were log-transformed. Only parameters which were independently associated with *β*-cell function indices after multiple stepwise regression are shown. ^†^ *P* \< 0.01; ^\#^ *P* \< 0.001.

###### 

Multiple linear regression for *β*-cell function after grouping by gender.

                                    INSR30   INSR120      DI30     DI120                                       
  --------------------------------- -------- ------------ -------- ------------ -------- ------------ -------- ------------
  Female                                                                                                        
   Hypertension (yes = 1, no = 0)   −0.016   −0.012       −0.023   −0.015       ---      ---          ---      ---
   Years from diagnosis             −0.024   −0.216^\#^   −0.034   −0.268^\#^   −0.020   −0.256^\#^   −0.030   −0.331^\#^
   BMI (kg^2^/cm)                   0.015    0.082\*      0.010    0.050        ---      ---          ---      ---
   SBP (mmHg)                       ---      ---          ---      ---          0.001    0.051        0.001    0.008
   DBP (mmHg)                       ---      ---          ---      ---          −0.006   −0.125\*     −0.006   −0.111\*
   HbA1c (%)                        −0.114   −0.409^\#^   −0.155   −0.490^\#^   −0.069   −0.366^\#^   −0.109   −0.491^\#^
   sUA (*μ*mol/L)                   0.001    0.115^†^     0.001    0.107^†^     0.001    0.143^†^     0.001    0.143^\#^
   TG (mmol/L)                      0.021    0.017        0.046    0.032        ---      ---          ---      ---
   TC (mmol/L)                      ---      ---          ---      ---          −0.052   −0.130       −0.074   −0.159
   HDL (mmol/L)                     −0.065   −0.029       −0.131   −0.052       ---      ---          ---      ---
   LDL (mmol/L)                     ---      ---          ---      ---          0.039    0.070        0.063    0.098
   ALT (IU/L)                       0.106    0.096\*      0.117    0.094\*      ---      ---          ---      ---
   HOMA-IR                          0.456    0.435^\#^    0.412    0.345^\#^    −0.275   −0.384^\#^   −0.309   −0.367^\#^
  Male                                                                                                          
   Hypertension (yes = 1, no = 0)   −0.024   −0.016       −0.006   −0.004       ---      ---          ---      ---
   Years from diagnosis             −0.017   −0.134^\#^   −0.026   −0.186^\#^   −0.014   −0.187^\#^   −0.023   −0.258^\#^
   BMI (kg^2^/cm)                   0.026    0.116^\#^    0.024    0.100^†^     ---      ---          ---      ---
   SBP (mmHg)                       ---      ---          ---      ---          0.001    0.034        0.001    0.021
   DBP (mmHg)                       ---      ---          ---      ---          −0.003   −0.056       −0.005   −0.086\*
   HbA1c (%)                        −0.116   −0.395^\#^   −0.154   −0.474^\#^   −0.075   −0.423^\#^   −0.112   −0.526^\#^
   sUA (*μ*mol/L)                   0.001    0.163^\#^    0.002    0.169^\#^    0.001    0.201^\#^    0.001    0.212^\#^
   TG (mmol/L)                      −0.026   −0.023       0.001    0.001        ---      ---          ---      ---
   TC (mmol/L)                      ---      ---          ---      ---          0.004    0.033        0.002    0.003
   HDL (mmol/L)                     −0.088   −0.034       −0.064   −0.022       ---      ---          ---      ---
   LDL (mmol/L)                     ---      ---          ---      ---          −0.036   −0.063       −0.021   −0.030
   ALT (IU/L)                       0.075    0.060\*      0.083    0.060\*      ---      ---          ---      ---
   HOMA-IR                          0.522    0.469^\#^    0.430    0.350^\#^    −0.202   −0.304^\#^   −0.283   −0.353^\#^

*Β*: partial regression coefficient; S-*β*: standard partial regression coefficient. All abnormally distributed continuous variables were log-transformed. Only parameters which were independently associated with *β*-cell function indices after multiple stepwise regression are shown. \**P* \< 0.05; ^†^ *P* \< 0.01; ^\#^ *P* \< 0.001.
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